Adjuvant therapy of the very young woman

Breast

Volumn 16, Issue 2 SUPPL., 2007, Pages 136-146

  Pritchard, Kathleen I ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adjuvant therapy; Breast cancer; Fertility; Premature menopause; Quality of life; Very young women

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GOSERELIN; LETROZOLE; LEUPRORELIN; METHOTREXATE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ADOPTION; ADULT; AGE; AMENORRHEA; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYOPRESERVATION; DISEASE FREE SURVIVAL; DYSPAREUNIA; EARLY MENOPAUSE; ENDOMETRIUM ABLATION; FEMALE; FEMALE FERTILITY; FERTILIZATION IN VITRO; GENE EXPRESSION PROFILING; GENE MUTATION; HORMONAL THERAPY; HUMAN; INTERMETHOD COMPARISON; LIBIDO DISORDER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OOCYTE; ORGASM DISORDER; OVARY INSUFFICIENCY; OVERALL SURVIVAL; PATIENT COUNSELING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SYMPTOM; TERATOGENICITY;

EID: 35648942641     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.07.023     Document Type: Article

References (132)

1. Canadian Cancer Society Statistics 2006. 〈www.cancer.ca〉
2. Albain K., Allred C., and Clark G. Breast cancer outcome and predictors of outcome: are there age differentials?. J Natl Cancer Inst Monogr (1994) 35-42
3. Walker R.A., Lees E., Webb M., and Dearing S.J. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer 74 (1996) 1796-1800
4. Adami H.O., Malker B., Holmberg L., Persson I., and Stone B. The relation between survival and age at diagnosis in breast cancer. New Engl J Med 315 (1986) 559-563
5. Chung M., Chang H.R., Bland K.I., and Wanebo H.J. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 77 (1996) 97-103
6. Winchester D.P., Osteen R.T., and Menck H.R. The National Cancer Data Base Report on breast carcinoma characteristics and outcome in relation to age. Cancer 78 (1996) 1838-1843
7. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program public-use CD-ROM (1973-1997). Cancer Surveillance Program Cancer Statistics, 1999.
8. Holli K., and Isola J. Effect of age on the survival of breast cancer patients. Eur J Cancer 33 (1997) 425-428
9. Swanson G., and Lin C. Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr 16 (1994) 69-77
10. Kroman N., Jensen M.B., and Wohlfahrt J. Factors influencing the effect of age on prognosis in breast cancer: population based study. Br Med J 320 (2000) 474-478
11. Colleoni M., Rotmensz N., Robertson C., et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13 (2002) 273-279
12. Bertheau P., Steinberg S.M., Merino M.J., et al. C-erbB-2, p53 and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol 29 (1998) 323-329
13. Pagani O., O'Neil A., Castiglione M., et al. Prognostic impact of amenorrhea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34 (1998) 632-640
14. Parulekar W., Day A.G., Ottaway J.A., et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA.5. J Clin Oncol 23 (2005) 6002-6008
15. Aebi S., Gelber R., and Castiglione-Gertsch M. Is chemotherapy alone adequate for young women with estrogen-receptor-positive breast cancer. Lancet 365 (2000) 1869-1874
16. Lethaby A.E., O'Neill M.A., Mason B.H., et al. Overall survival from breast cancer in women pregnant or lactating at or after diagnosis. Int J Cancer 67 (1996) 751-755
17. Bonnier P., Romain S., and Julien J.P. Influence of pregnancy on the outcome of breast cancer: a case-control study. Int J Cancer 72 (1997) 720-727
18. Tretli S., Kvatheim G., Thoresen S., and Host H. Survial of breast cancer patients diagnosed during pregnancy or lactation. Int J Cancer 58 (1988) 352-384
19. Turchetti D., Cortesi L., Federico M., et al. BRCA1 mutations and clinicopathological features in a sample of Italian women with early onset breast cancer. Eur J Cancer 36 (2000) 2083-2089
20. Peto J., Collins N., Barfoot R., et al. Prevalence of BRCA1 and BRCA2 gene mutation in patients with early-onset breast cancer. J Natl Cancer Inst 91 (1999) 943-949
21. Robson M., Gilewski T., Haas B., et al. BRCA-associated breast cancer in young women. J Clin Oncol 16 (1998) 1642-1649
22. Averette H.E., Boike G.M., and Jarrell M.A. Effects of cancer chemotherapy on gonadal function and reproductive capacity. Cancer J Clin 40 (1990) 199-209
23. Partridge A.H., Gelber S., and Gelber R. Delayed premature menopause following chemotherapy for early stage breast cancer: long term results from IBCSG Trial V. Proc Am Soc Clin Oncol 16 (2005) 50
24. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 169 (2000) 123-131
25. Knobf M.T. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist 11 (2006) 96-110
26. Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M., and Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17 (1999) 2365-2370
27. Bonadonna G., Valagussa P., Rossi A., et al. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5 (1985) 95-115
28. Laporsi E., and Weber B. The effects of breast cancer chemotherapy on menstrual functions. Proc Am Soc Clin Oncol 17 (1998) 155a
29. Sukumvanich P., Petrek J.A., Naughton M.J., et al. Incidence and time course of bleeding after long term amenorrhea following breast cancer treatment: a prospective study. Proc Am Soc Clin Oncol 16 (2005) 22a
30. Ganz P.A., Rowland J.H., Desmond K., Meyerowitz B.E., and Wyatt G.E. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 16 (1998) 501-514
31. Knobf M.T. Carrying on: the experience of premature menopause in women with early stage breast cancer. Nurs Res 51 (2002) 9-17
32. Dunn J., and Stegings S. Young Women's experience of breast cancer: defining young and identifying concerns. Psycho-Oncology 9 (2000) 137-146
33. Wilmoth M. The aftermath of breast cancer: an altered sexual self. Cancer Nurs 24 (2001) 278-286
34. Avis N., Crawford S., and Manuel J. Psychosocial problems among younger women with breast cancer. Psychooncology 13 (2004) 295-308
35. Dow K., Ferrell B.R., and Haberman M. The meaning of quality of life in cancer survivorship. Oncol Nurs Forum 26 (1999) 519-528
36. Ganz P.A., Coscarelli A., and Fred C. Breast cancer survivors psychosocial concerns and quality of life. Br Cancer Res Treat 38 (1996) 183-199
37. Ganz P.A., Greendale G.A., Petersen L., Kahn B., and Bower J.E. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol 21 (2003) 4184-4193
38. Cimprich B., Ronis D.L., and Martinez-Ramos G. Age at diagnosis and quality of life in breast cancer survivors. Cancer Pract 10 (2002) 85-93
39. Goodwin P.J., and Ennis M. Association of young age and chemotherapy with psychosocial distress and health-related quality of life (HRQOL) during the first year after breast cancer (BC). Proc Am Soc Clin Oncol 22 (2004) 732s
40. Bloom J.R., and Kessler L. Risk and timing of counseling and support intervention for younger women with breast cancer. JNCI Monogr 16 (1994) 199-206
41. Vinokur A., Threatt B., and Vinokur-Kaplan D. The process of recovery from breast cancer for younger and older patients: changes during the first year. Cancer 65 (1990) 1242-1254
42. Mor V., Malin M., and Allen S. Age differences in the psychosocial problems encountered by breast cancer patients. J Natl Cancer Inst Monogr 16 (1994) 191-197
43. Ferrell B.R., and Grant M. Quality of life in breast cancer. Cancer Pract 4 (1996) 331-340
44. Wang X., Cosby L., and Harris M. Major concerns and needs of breast cancer patients. Cancer Nurs 22 (1999) 157-168
45. Spencer S., Lehman J., and Wynings C. Concerns about breast cancer and relations to psychosocial well-being in a multiethnic sample of early-stage patients. Health Psychol 18 (1999) 159-168
46. Wenzel L., Fairclough D., and Brady M. Age-related differences in the quality of life of breast carcinoma patients after treatment. Cancer 86 (1999) 1768-1774
47. Arora N., Gustafson D., and Hawkins R. Impact of surgery and chemotherapy on the quality of life of younger women with breast carcinoma: a prospective study. Cancer 92 (2001) 1288-1298
48. Kroenke C.H., Rosner B., Chen W.Y., Kawachi I., Colditz G.A., and Holmes M.D. Functional Impact of breast cancer by age at diagnosis. J Clin Oncol 22 (2004) 1849-1856
49. Ganz P.A., Kwan L., Stanton A.L., Krupnick J.L., et al. Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst 96 (2004) 376-387
50. International Breast Cancer Study Group. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet 347 (1996) 1279-1284
51. Schag C.A., Ganz P.A., Polinsky M.L., Fred C., Hirji K., and Petersen L. Characteristics of women at risk for psychosocial distress in the year after breast cancer. J Clin Oncol 11 (1993) 783-793
52. Schnipper H.H. Life after breast cancer. J Clin Oncol 19 (2001) 3581-3584
53. Carpenter J., Johnson D.H., Wagner L., et al. Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum 29 (2002) E16-E25
54. Carpenter J., Elam J.L., Ridner S.H., et al. Sleep, fatigue and depressive symptoms in breast cancer survivors and matched healthy women experiencing hot flashes. Oncol Nurs Forum 31 (2004) 591-598
55. Couzi R.J., Helzlsouer K.J., and Fetting J.H. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 13 (1995) 2737-2744
56. Knobf M.T. The influence of symptom distress and preparation on responses of women with early stage breast cancer to induced menopause. Psychooncology 8 (1999) 88a
57. Ganz P.A., Desmond K.A., Belin T.R., Meyerowitz B.E., and Rowland J.H. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 17 (1999) 2371
58. Lindley C., Vasa S., Sawyer W.T., and Winer E.P. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 16 (1998) 1380-1387
59. Rogers M., and Kritjanson L.J. The impact on sexual functioning of chemotherapy-induced menopause in women with breast cancer. Cancer Nurs 25 (2002) 57-65
60. Young-McCaughan S. Sexual functioning in women with breast cancer after treatment with adjuvant therapy. Cancer Nurs 19 (1996) 308-319
61. Dorval M., Maunsell E., Deschenes L., et al. Long-term quality of life after breast cancer: comparison of 8-year survivors with population controls. J Clin Oncol 16 (1998) 487-494
62. Knobf M.T. Symptom distress before, during and after adjuvant breast cancer therapy. Dev Support Cancer Care 4 (2000) 13-17
63. Ganz P.A., Desmond K.A., Leedham B., et al. Quality of life in long-term disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 94 (2002) 39-49
64. Barton D., Wilwerding M., Carpenter L., et al. Libido as part of sexuality in female cancer survivors. Oncol Nurs Forum 31 (2004) 599-607
65. Goldhirsch A., and Gelber R.D. Life with consequences of breast cancer: pregnancy during and after endocrine therapies. Breast 13 (2004) 443-445
66. Barthelmes L., and Gateley C.A. Tamoxifen and pregnancy. Breast 13 (2004) 446-451
67. Partridge A.H., and Schapira L. Pregnancy and breast cancer: epidemiology, treatment and safety issues. Oncology 19 (2005) 693-697
68. Dow K., and Kuhn D. Fertility options in young breast cancer survivors: a review of the literature. Oncol Nurs Forum 31 (2004) E46-E63
69. Sonmezer M., and Oktay K. Fertility preservation in female patients. Hum Reprod 10 (2004) 251-266
70. Falcone T., Attaran M., Bedaiwy M.A., et al. Ovarian function preservation in the cancer patient. Fertil Steril 81 (2004) 243-257
71. Oktay K., and Sonmezer M. Ovarian tissue banking for cancer patients: fertility preservation, not just cryopreservation. Hum Reprod 19 (2004) 477-480
72. Oktay K., Buyuk E., Davis O., et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 18 (2003) 90-95
73. Oktay K., Buyuk E., Libertella N., et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23 (2005) 4347-4353
74. Anderson R.A., Kinniburgh D., and Baird D.T. Preliminary experience of the use of a gonadotropin-releasing hormone antagonist in ovulation induction/in-vitro fertilization prior to cancer treatment. Hum Reprod 14 (1999) 2665-2668
75. Radford J.A., Shalet S., and Lieberman B. Fertility after treatment for cancer: questions remain over ways of preserving ovarian and testicular tissue. Br Med J 319 (1999) 935-936
76. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers. Mol Cell Endocrinol 187 (2002) 93-105
77. Simon B., Lee S.J., Partridge A.H., et al. Preserving fertility after cancer. Cancer J Clin 55 (2005) 211-228
78. Blumenfeld Z., and Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. Monogr Natl Cancer Inst 34 (2005) 40-43
79. Fox K., Scialia J., and Moore H. Preventing chemotherapy-related amenorrhea using leuprolide during adjuvant chemotherapy for early stage breast cancer. Proc Am Soc Clin Oncol 22 (2003) 13a
80. Del Mastro L., Catzeddu T., Boni L., et al. Temporary ovarian suppression with goserelin for prevention of chemotherapy induced menopause in young early stage breast cancer patients: results of a phase II study. Am Soc Clin Oncol 16s (2005) 662a
81. Recchia F., Sica G., DeFilippis S., et al. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anticancer Drugs 13 (2002) 417-424
82. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N Engl J Med 319 (1988) 1681-1692
83. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339 (1992) 1-15A-71-85
84. Pritchard K.I. Ovarian ablation as adjuvant therapy for premenopausal women with early breast cancer: Phoenix arisen? (Editorial). Lancet 339 (1992) 95-96
85. EBCTCG. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 366 (2005) 2087-2106
86. Taylor C.W., Green S., Dalton W.S., et al. Multicentere randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an Intergroup Study. J Clin Oncol 16 (1998) 994-999
87. Boccardo F., Blamey R., Klijn J.C.M., Tominaga T., Duchateau L., and Sylvester R. LHRH-Agonist (LHRH-A)+tamoxifen (TAM) versus LHRH-A alone in premenopausal women with advanced breast cancer (ABC): results of a meta-analysis of four trials. Proc Am Soc Clin Oncol 18 (1999) 110a
88. Davidson N.E., O'Neill A.M., Vukov A.M., et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 23 (2005) 5973-5982
89. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 Randomized Trial. J Clin Oncol 19 (2001) 602-611
90. Rutqvist L.E. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: a randomized trial by the Cancer Research Compaign (C.R.C.) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Group & the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (G.I.V.I.O.). Proc Am Soc Clin Oncol 18 (1999) 67a
91. Nystedt M., Berglund G., Bolund C., Fornander T., and Rutqvist L.E. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol 21 (2003) 1836-1844
92. Scottish Cancer Trials Breast Group. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 341 (1993) 1293-1298
93. Engelsman E., Klijn J.C.M., Rubens R.D., et al. Classical CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. Eur J Cancer 27 (1991) 966-970
94. Ejlertsen B., Dombernowski P., Mouridsen H.T., et al. Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP). Proc Am Soc Clin Oncol 18 (1999) 66a
95. Jakesz R., Hausmaninger H., Kubista E., et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and Fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-austrian breast and colorectal cancer study group trial. J Clin Oncol 20 (2002) 4621-4627
96. Jonat W., Kaufmann M., Sauerbrei W., et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20 (2002) 4628-4635
97. von Minckwitz G., Graf E., Geberth M., et al. Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients: the GABG IV-A-93 trial. ASCO Proc 23 (2004) 10
98. Wallwiener D., Possinger K., Schmid P., et al. A phase III trial comparing adjuvant treatment with leuprorelin acetate 3M-Depot for 24 months with CMF chemotherapy in ER/PR+node+pre-perimenopausal breast cancer patients. ASCO Proc 23 (2004) 10
99. Bernhard J., Zahrieh D., Castiglione-Gertsch M., et al. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients-the International Breast Cancer Study Group Trial VIII. J Clin Oncol 25 (2007) 263-270
100. Roche H., Kerbrat P., Bonneterre J., Fumoleau P., and Monnier A. Complete hormonal, blockade versus chemotherapy in premenopausal early-stage breast cancer patients (pts) with positive hormone receptor (HR+) and 1-3 node-positive (N+) tumor: results of the FASG 06 trial. ASCO Proc (2000)
101. Boccardo F., Rubagotti A., Amoroso D., et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18 (2000) 2718-2727
102. Levine M.N., Bramwell V.H., Pritchard K.I., et al. A randomized trial of cyclophosphamide, epirubicin, fluorouracil chemotherapy compared with cyclophosphamide, methrotrexate, fluorouracil in premenopausal women with node positive breast cancer. J Clin Oncol 16 (1998) 2651-2658
103. Citron M., Berry D.A., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and leukemia group B trial 9741. J Clin Oncol 21 (2003) 1431-1439
104. Burnell M, Levine M, Chapman JA, et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer. NCIC CTG MA.21 Results of an interim analysis. Late Breaking Abstract Presentation, 2006.
105. Pritchard K.I. Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift?. J Clin Oncol 20 (2002) 4611-4614
106. Abrams, J. Personal Communication, 2007.
107. Ward H.W.C. Antiestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1 (1973) 13-14
108. Pritchard K.I., Thomson D.B., Myers R.E., Sutherland D.J.A., Mobbs B.G., and Meakin J.W. Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64 (1980) 787-796
109. Ribeiro G.G., and Swindell R. The Christie hospital adjuvant tamoxifen trial-status at 10 years. Br J Cancer 57 (1988) 601-603
110. Scottish Cancer Trials Breast Group. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet (1987) 171-175
111. Rose C., Andersen K.W., and Mouridsen H.T. Beneficial effect of adjuvant tamoxifen in primary breast cancer patients with high oestrogen receptor values. Lancet 1 (1985) 16-19
112. Pritchard K.I., Meakin J.W., Boyd N.F., et al. Treatment of Early Breast Cancer. vol. 1, World Wide Evidence 1985-1990: a randomized trial of adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer. 1st ed (1990), Oxford Medical Publishers, Oxford
113. Nolvadex Adjuvant Trial Organization. Controlled trial of tamoxifen as a single adjuvant agent in management of early breast cancer. Analysis at eight years by the Nolvadex Adjuvant Trial Organization. Br J Cancer 57 (1988) 608-611
114. Fisher B., Costantino J., Redmond C., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320 (1989) 479-484
115. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351 (1998) 1451-1467
116. Peto R. September 21-23, 2000. Personal Communication.
117. Bramwell V.H., and Pritchard K.I. Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: is it standard practice or still a subject for study?. Eur J Cancer 35 (1999) 1625-1627
118. Andersson M., Kamby C., Jensen M.B., et al. Danish Breast Cancer Cooperative Group. Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Eur J Cancer 35 (1999) 1659-1666
119. Hutchins L., Green S.J., Ravdin P.M., et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol 23 (2005) 8313-8321
120. Osborne C.K. Effects of estrogen and antiestrogens on cell proliferation. Implications for treatment of breast cancer. In: Osborne C.K. (Ed). Endocrine treatment in breast and prostate cancer (1988), Kluwer, Boston 11-129
121. Goldenberg G.J., and Froese E.K. Antagonism of the cytocidal activity and uptake of an melphalan by tamoxifen in human breast cancer cells in vitro. Biochem Pharmacol 34 (1985) 763-770
122. Albain K., Green S.J., Ravdin P.M., et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup Trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 21 (2002) 37a
123. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 19-93. J Clin Oncol 24 (2006) 1332-1341
124. Paridaens R., Dyczka J., Rutgers E., et al. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer. First results of a randomized phase III trial EORTC 10901. EJC Supplements fourth European breast cancer conference 2 (2004) 70
125. Bramwell, V. Personal Communication. NCIC CTG MA.12, 2007.
126. Hutchins L., Green S., Ravdin P., et al. CMF versus CAF +/- tamoxifen in high-risk node-negative breast cancer patients and a natural history of follow-up study in low-risk node negative patients: Update of tamoxifen results. Breast Cancer Res Treat 57 (1999) 25
127. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21 (2003) 976-983
128. Piccart-Gebhart M., Procter M., Leyland-Jones B., et al. Trastuzumab after chemotherapy in HER2-positive breast cancer. New Engl J Med 353 (2005) 1659-1672
129. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 369 (2007) 29-36
130. Romond E., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable her2-positive breast cancer. New Engl J Med 353 (2005) 1673-1674
131. Bartelink H., Horiot J.C., Poortmans P.M., Struikmans H., et al. Impact of radiation dose on local control, fibrosis and survival after breast conserving treatment: 10 year results of the EORTC trial 22881-10882. Br Cancer Res Treat 100 (2006) S8-S10
132. Van De Vijver M., He Y.D., Van'T Veer L., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009